Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade
Authors
Keywords
-
Journal
LIVER INTERNATIONAL
Volume 36, Issue 8, Pages 1176-1186
Publisher
Wiley
Online
2015-12-30
DOI
10.1111/liv.13055
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer
- (2015) Dean Yimlamai et al. JOURNAL OF HEPATOLOGY
- Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion
- (2015) Hui-Hui Cao et al. Molecular Cancer
- Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer Research
- (2014) Xin Chen et al. AMERICAN JOURNAL OF PATHOLOGY
- 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice
- (2014) Chunmei Wang et al. HEPATOLOGY
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- Met as a therapeutic target in HCC: Facts and hopes
- (2013) Silvia Giordano et al. JOURNAL OF HEPATOLOGY
- Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
- (2013) Matthias S. Matter et al. JOURNAL OF HEPATOLOGY
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- mTOR Complex 1 Plays Critical Roles in Hematopoiesis and Pten-Loss-Evoked Leukemogenesis
- (2012) Demetrios Kalaitzidis et al. Cell Stem Cell
- Targeted Therapies for Hepatocellular Carcinoma
- (2011) Augusto Villanueva et al. GASTROENTEROLOGY
- AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2,
- (2011) Coral Ho et al. HEPATOLOGY
- Management of hepatocellular carcinoma: An update
- (2011) Jordi Bruix et al. HEPATOLOGY
- The Critical Role of AKT2 in Hepatic Steatosis Induced by PTEN Loss
- (2010) Lina He et al. AMERICAN JOURNAL OF PATHOLOGY
- Expansion of Hepatic Tumor Progenitor Cells in Pten-Null Mice Requires Liver Injury and Is Reversed by Loss of AKT2
- (2010) Vivian A. Galicia et al. GASTROENTEROLOGY
- Increased Lipogenesis, Induced by AKT-mTORC1-RPS6 Signaling, Promotes Development of Human Hepatocellular Carcinoma
- (2010) Diego F. Calvisi et al. GASTROENTEROLOGY
- mTORC1 controls fasting-induced ketogenesis and its modulation by ageing
- (2010) Shomit Sengupta et al. NATURE
- AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
- (2009) Krishna M. Vasudevan et al. CANCER CELL
- Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis
- (2009) C.-R. Xu et al. MOLECULAR CANCER RESEARCH
- Role of Cyclin D1 as a Mediator of c-Met- and -Catenin-Induced Hepatocarcinogenesis
- (2008) M. A. Patil et al. CANCER RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Class I PI3K in oncogenic cellular transformation
- (2008) L Zhao et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started